Welcome to our dedicated page for SAB BIOTHERAPEUTICS news (Ticker: SABSW), a resource for investors and traders seeking the latest updates and insights on SAB BIOTHERAPEUTICS stock.
SAB Biotherapeutics, Inc. (SAB BIO), whose exchange-listed warrants trade under the symbol SABSW, is a clinical-stage biopharmaceutical company that regularly issues news about its lead program SAB-142 and its broader human immunoglobulin platform. Company press releases describe SAB BIO as focused on developing multi-specific, high-potency human immunoglobulin G (hIgG) and human anti-thymocyte immunoglobulin (hATG) therapies for immune and autoimmune disorders, with a primary emphasis on autoimmune type 1 diabetes (T1D).
News coverage for SAB BIO often centers on clinical milestones for SAB-142, a multi-specific, fully human anti-thymocyte globulin in development as a potentially disease-modifying, redosable immunotherapy for Stage 3 T1D. Recent announcements include positive Phase 1 safety and pharmacodynamic data, initiation and enrollment progress in the Phase 2b SAFEGUARD trial, and presentations of SAB-142 data at major diabetes conferences such as the European Association for the Study of Diabetes (EASD), the International Society for Pediatric and Adolescent Diabetes (ISPAD), and the Asian Conference on Innovative Therapies for Diabetes Management.
Investors following SABSW-related news will also see updates on SAB BIO’s corporate and financial developments. The company has reported participation in healthcare investor conferences, financing transactions such as the private placement of Series B Convertible Preferred Stock and warrants, and governance updates including board appointments. SEC-related announcements, such as proxy materials for stockholder meetings to approve share issuances and equity plan amendments, are another recurring theme.
Because SAB BIO’s strategy is to advance SAB-142 as a therapy that may change the treatment paradigm for autoimmune type 1 diabetes, many news items highlight mechanistic data, safety findings, and trial design details that support this goal. For readers tracking SABSW and SAB Biotherapeutics, the news stream provides insight into clinical progress, regulatory interactions, capital structure decisions, and scientific visibility through conference presentations. Bookmarking this page allows ongoing access to company press releases and third-party coverage linked to SABSW and the underlying SAB Biotherapeutics common stock.
SAB Biotherapeutics (Nasdaq: SABS) reported its Q2 2022 financial results, highlighting a cash position of $16.6 million and a net loss of $4.8 million with EPS of $(0.11). Operating expenses are projected to be covered for the next twelve months. The company is advancing its pipeline with SAB 176 for anti-influenza entering Phase II development and SAB 195 targeting C. diff. moving towards pre-IND. A virtual R&D update is scheduled for August 17, 2022, to showcase its polyclonal immunotherapy platform, DiversitAb™.
SAB Biotherapeutics (SABS) has terminated its agreement with the U.S. Department of Defense due to misalignment of goals following modifications during the COVID-19 pandemic. This allows SAB to refocus on its core mission and advance its research pipeline, including the development of SAB-195, a polyclonal antibody treatment for Clostridioides difficile infection (CDI), which affects 500,000 people annually in the U.S. alone. SAB plans to file an IND within 18 months and anticipates announcing Phase 1 clinical trial results in 2024.
SAB Biotherapeutics (NASDAQ: SABS) announced a Virtual 2022 Annual R&D Portfolio Update on August 17, 2022, at 10:30 a.m. ET. The update will showcase the company's unique DiversitAb™ immunotherapy platform that produces high-potency, fully-human polyclonal antibodies without human donors. Executives will discuss planned clinical and preclinical development programs targeting diseases like COVID-19 and type 1 diabetes. A live webcast will be available, with a replay on the company's website. For registration details, visit www.sab.bio.
SAB Biotherapeutics (Nasdaq: SABS) announced the appointment of Rear Admiral Scott Giberson to its Board of Directors, effective July 7, 2022. Giberson, a retired two-star admiral with extensive government and healthcare experience, will bring valuable insights to the company. His previous roles include Deputy Surgeon General and Commander of the Commissioned Corps’ Ebola Response. SAB aims to leverage Giberson’s expertise to address unmet medical needs through its innovative immunotherapy platform. The company focuses on developing fully human polyclonal antibodies targeting diseases like COVID-19 and type 1 diabetes.
SAB Biotherapeutics (SABS) hosted Congressmen Dusty Johnson and Dean Phillips on July 1, 2022, at its Sioux Falls facility. The visit showcased SAB's innovative immunotherapy platform that produces fully human polyclonal antibodies through genetically engineered cattle. The Congressmen engaged with SAB's management team, discussing advancements in COVID-19 treatment and the company's pipeline targeting influenza, oncology, and type 1 diabetes. SAB aims to address unmet global health needs with its DiversitAb™ platform.
SAB Biotherapeutics (Nasdaq: SABS) announced the appointment of Dr. Alexandra Kropotova as Chief Medical Officer to enhance its pipeline in immune and autoimmune disorders. With over 20 years of experience, Dr. Kropotova previously led drug development at Teva Pharmaceuticals and has held key roles at Sanofi and Pfizer. Her expertise is expected to be vital for advancing SAB's initiatives in areas such as infectious diseases and cancer. The company continues to leverage its innovative platform for producing high-potency, fully human polyclonal antibodies.
SAB Biotherapeutics will present at the Large Animal Genetic Engineering Summit on June 7, 2022, in Park City, Utah. CEO Dr. Christoph Bausch will discuss advancements in their Transchromosomic (Tc) Goat platform for producing fully human polyclonal antibodies. The presentation will cover the DiversitAb platform, highlighting pipeline programs including SAB-185 (anti-SARS-CoV-2), SAB-176 (influenza), and SAB-142 (Type 1 diabetes). The company focuses on innovative immunotherapy solutions aimed at serious diseases.
SAB Biotherapeutics (Nasdaq: SABS) reported its Q1 2022 financial results and company updates, emphasizing significant advancements in its immunotherapy platform.
Key highlights include:
- Cash and cash equivalents of $22.4 million as of March 31, 2022.
- R&D expenses increased to $13.3 million, attributed to expanded capabilities.
- Net income was $1 million, equating to $0.02 per share.
Full data from the Phase 2a trial for SAB-176 is expected in Q3 2022, with additional updates on SAB-185 and other pipeline candidates anticipated later this year.
SAB Biotherapeutics (NASDAQ: SABS) will participate in the H.C. Wainwright Global Investment Conference from May 23-26, 2022. The company's management team is scheduled for a live Fireside Chat on May 25, 2022, at 9:00 am EDT. An on-demand webcast will be available on their website, allowing investors to access the presentation for 90 days post-event. SAB Biotherapeutics focuses on developing immunotherapies using fully human polyclonal antibodies for various diseases, including COVID-19 and type 1 diabetes.
SAB Biotherapeutics has appointed Dr. Mark J. Ratain to its Board of Scientific Advisors to enhance its oncology platform. Dr. Ratain, a prominent expert in cancer treatment and clinical pharmacology, has published over 500 academic works and will contribute his extensive knowledge to advance SAB's fully-human polyclonal antibody therapies.
CEO Eddie J. Sullivan expressed enthusiasm about Dr. Ratain's addition, emphasizing the potential benefits for the company’s targeted multivalent immunotherapies aimed at treating cancer.